Significance of different parameters on survival in 109 patients with MCL as determined by the log-rank test
| Parameter . | Median OS, mo . | Log-rank, P . |
|---|---|---|
| Age | < .001 | |
| 68 or younger, n = 53 | 49 | |
| Older than 68, n = 56 | 23 | |
| Sex | .88 | |
| Male, n = 89 | 39 | |
| Female, n = 20 | 35 | |
| Morphology | .72 | |
| Classical, n = 83 | 38 | |
| Blastoid variant, n = 26 | 36 | |
| Stage | .10 | |
| I-II, n = 9 | 47 | |
| III-IV, n = 92 | 37 | |
| IPI | .006 | |
| 0-2, n = 39 | 64 | |
| 3-5, n = 49 | 26 | |
| s-LDH | .004 | |
| 6.7 μkat/L or less, n = 46 | 65 | |
| More than 6.7 μkat/L, n = 46 | 25 | |
| Spleen involvement | .21 | |
| Yes, n = 45 | 36 | |
| No, n = 62 | 42 | |
| Tonsil involvement | .73 | |
| Yes, n = 17 | 38 | |
| No, n = 90 | 37 | |
| GI tract involvement | .93 | |
| Yes, n = 15 | 38 | |
| No, n = 92 | 35 | |
| VH gene mutation status | .28 | |
| Mutated, n = 18 | 18 | |
| Unmutated, n = 91 | 39 | |
| VH3-21 use | .030 | |
| Yes, n = 21 | 53 | |
| No, n = 88 | 34 |
| Parameter . | Median OS, mo . | Log-rank, P . |
|---|---|---|
| Age | < .001 | |
| 68 or younger, n = 53 | 49 | |
| Older than 68, n = 56 | 23 | |
| Sex | .88 | |
| Male, n = 89 | 39 | |
| Female, n = 20 | 35 | |
| Morphology | .72 | |
| Classical, n = 83 | 38 | |
| Blastoid variant, n = 26 | 36 | |
| Stage | .10 | |
| I-II, n = 9 | 47 | |
| III-IV, n = 92 | 37 | |
| IPI | .006 | |
| 0-2, n = 39 | 64 | |
| 3-5, n = 49 | 26 | |
| s-LDH | .004 | |
| 6.7 μkat/L or less, n = 46 | 65 | |
| More than 6.7 μkat/L, n = 46 | 25 | |
| Spleen involvement | .21 | |
| Yes, n = 45 | 36 | |
| No, n = 62 | 42 | |
| Tonsil involvement | .73 | |
| Yes, n = 17 | 38 | |
| No, n = 90 | 37 | |
| GI tract involvement | .93 | |
| Yes, n = 15 | 38 | |
| No, n = 92 | 35 | |
| VH gene mutation status | .28 | |
| Mutated, n = 18 | 18 | |
| Unmutated, n = 91 | 39 | |
| VH3-21 use | .030 | |
| Yes, n = 21 | 53 | |
| No, n = 88 | 34 |
OS indicates overall survival.
Median age at diagnosis was 68 years.